TICKERNERD
Menu
ZNTLZNTLHealthcare · Biotechnology

ZNTL Stock Forecast: Zentalis Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$1.96
−1.51% on the day

The 11 Wall Street analysts covering Zentalis Pharmaceuticals, Inc. hold a median 12-month price target of $8 — +308.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 59 of 100 as at 31 Oct 2026 — in the upper half.

Market cap
$192.3M
Ticker Nerd rank
59/ 100
Median analyst target
$8.00
Analysts covering
11
Revenue$0.0
Operating income−$44.4M
Net income−$42.3M
Free cash flow−$37.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−11.3%
1M
−29.2%
YTD
+45.2%
1Y
+32.0%
From 52W high
−70.3%
From 52W low
+53.1%
$1.28
$6.61
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ZNTL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Zentalis Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
59/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
87
Accruals
73
Size
67
Momentum
60
Quality
56
Value
49
Growth
46
Revisions
36
Volatility
14

Issuance (87): The share count has been shrinking and the company is not leaning on new borrowing.

Volatility (14): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ZNTL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ZNTL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Jan 26Apr 26Jul 26Oct 26ZNTLHigh $10.00Median $8.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
8 Buy3 Hold0 Sell
Low $5.00Median $8.00High $10.00

The green dot is the last close — the median target sits +308.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Oct 2026HC Wainwright & Co.ReiteratesBuy$10
5 Oct 2026Leerink PartnersAssumesOutperform$4.00 → $8.00
16 Sept 2026William BlairInitiatesOutperform—
16 Sept 2026William BlairInitiatesOutperform—
23 July 2026Rodman & RenshawInitiatesBuy—
17 July 2026MizuhoInitiatesOutperform$8.00
17 July 2026MizuhoInitiatesOutperform—
10 Apr 2026GuggenheimMaintainsBuy—
27 Mar 2026GuggenheimReiteratesBuy—
12 Nov 2025Morgan StanleyMaintainsEqual-Weight—
7 Aug 2025Wells FargoMaintainsEqual-Weight—
15 May 2025HC Wainwright & Co.ReiteratesBuy—
15 May 2025WedbushReiteratesNeutral—
28 Mar 2025WedbushReiteratesNeutral—
27 Mar 2025HC Wainwright & Co.ReiteratesBuy—
17 Mar 2025HC Wainwright & Co.ReiteratesBuy—
30 Jan 2025Wells FargoMaintainsEqual-Weight—
29 Jan 2025HC Wainwright & Co.MaintainsBuy—
28 Jan 2025UBSMaintainsNeutral—
15 Nov 2024GuggenheimMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ZNTL appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ZNTL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Zentalis Pharmaceuticals, Inc. returned +32.0% against +12.4% for the S&P 500, dividends included.

ZNTL vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500Jan 26Apr 26Jul 26Oct 26ZNTLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ZNTL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Zentalis Pharmaceuticals, Inc. (ZNTL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.0×

Cheaper than 83% of US stocks

Price / sales
—
Price / book
1.0×

Cheaper than 71% of US stocks

EV / EBITDA
−0.0×

Cheaper than 63% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−66.7%

Higher than 18% of US stocks

Return on assets
−33.2%

Higher than 12% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Zentalis Pharmaceuticals, Inc. (ZNTL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Zentalis Pharmaceuticals, Inc. has a market value of $192.3M and an enterprise value of $5.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$139.5M.

  • Free cash flow in the twelve months to 30 June 2026: −$128.1M.

  • Shares outstanding: 71.7M.

  • Trailing P/E: −1.0×; forward P/E: −1.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Zentalis Pharmaceuticals, Inc. employs 106 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 31 Oct 2026

Data provided by Twelve Data

Peers

ZNTL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ZNTLZentalis Pharmaceuticals, Inc.$192.3M59
WHWKWhitehawk Therapeutics, Inc.$184.7M71
UPBUpstream Bio, Inc.$186.8M26
RNAAtrium Therapeutics, Inc.$184.2M5
CGENCompugen Ltd.$187.2M78
YARWYarrow Bioscience, Inc.$187.8M60
RNACCartesian Therapeutics, Inc.$190.2M24

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Zentalis Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ZNTL news & analysis

Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026

GlobeNewsWire · 23 Oct 2026positive

Zentalis reported interim DENALI Part 1b results, including its first overall survival analysis for azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer, at the ESMO Congress 2026. The analysis used data through May 22, 2026.

Why it matters — The update provides ZNTL watchers with an overall survival data point from the clinical development of azenosertib in ovarian cancer.

Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract

GlobeNewsWire · 18 Oct 2026neutral

Zentalis Pharmaceuticals announced that overall survival data from an interim analysis of the DENALI Part 1b study (GOG-3066) have been published in an abstract for an upcoming rapid oral presentation at the ESMO Congress 2026.

Why it matters — The abstract provides a further update on clinical data for Zentalis’ investigational azenosertib program in ovarian cancer.

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 1 Oct 2026neutral

Zentalis Pharmaceuticals announced that on October 1, 2026, its Compensation Committee granted non-qualified stock options to purchase a total of 62,000 shares of common stock to three newly hired employees. The options were granted under the company's 2022 Employment Inducement Incentive Award Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters — ZNTL watchers would care because this discloses new equity compensation tied to recent hires, reflecting the company's ongoing talent acquisition under its inducement incentive plan.

This Small Biotech's Cancer Drug Could Reach $1.3 Billion In Peak Sales

Benzinga · 16 Sept 2026positive

Zentalis Pharmaceuticals received a bullish initiation from William Blair on Tuesday. The analyst sees a potential blockbuster opportunity for the biotech's lead cancer drug, azenosertib.

Why it matters — Zentalis watchers would care because a bullish analyst initiation highlights optimism about the commercial potential of its lead cancer drug, azenosertib.

Zentalis Pharmaceuticals, Inc. (ZNTL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 15 Sept 2026neutral

Zentalis Pharmaceuticals presented at the Morgan Stanley 24th Annual Global Healthcare Conference. A transcript of the company's presentation at the event is now available via Seeking Alpha.

Why it matters — The presentation gives ZNTL watchers insight into the company's latest corporate updates and strategy as communicated to the investment community.

FAQ

Frequently asked questions about ZNTL stock

What is the ZNTL stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Zentalis Pharmaceuticals, Inc. have a median 12-month price target of $8, with estimates ranging from $5 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ZNTL stock a buy right now?

Of the 11 analysts covering Zentalis Pharmaceuticals, Inc., 8 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Zentalis Pharmaceuticals, Inc. 59 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ZNTL?

As at 31 Oct 2026, Zentalis Pharmaceuticals, Inc. ranks 59 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (87 of 100).

Will ZNTL stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +308.2% from the last close, and Ticker Nerd's factor model ranks Zentalis Pharmaceuticals, Inc. 59 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ZNTL stock forecast for 2030?

No analyst covering Zentalis Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ZNTL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $10 over the next 12 months.

How has ZNTL stock performed over the past year?

Zentalis Pharmaceuticals, Inc. returned +32.0% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Zentalis Pharmaceuticals, Inc. do?

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for cancer.

What is the latest news on ZNTL?

The most recent item we track (GlobeNewsWire, 23 Oct 2026): "Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026". Zentalis reported interim DENALI Part 1b results, including its first overall survival analysis for azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer, at the ESMO Congress 2026. The analysis used data through May 22, 2026.

Company

About Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for cancer. Its current portfolio centers on azenosertib, an oral investigational WEE1 inhibitor being advanced in studies across ovarian cancer and other solid tumors. The company’s research emphasizes biomarker-driven oncology, with a focus on targeted, non-chemotherapy treatment approaches designed to address difficult-to-treat cancers. Zentalis also develops additional oncology candidates, including programs targeting hematologic malignancies and other cancer pathways, supported by its internal discovery capabilities and clinical development expertise. Headquartered in San Diego, California, Zentalis Pharmaceuticals plays a specialized role in the oncology market by advancing precision medicine candidates from discovery into late-stage clinical evaluation.

CEO Ms. Julie M. Eastland M.B.A. · 106 employees · United States · https://zentalis.com